B7-33 Nasal Spray

B7-33 Nasal Spray is a high-purity synthetic peptide formulated exclusively for in vitro and laboratory research applications. Available at Direct Anti Peptide at ≥98% purity, this compound is analytically verified by HPLC and mass spectrometry to meet rigorous research-grade standards. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Product Overview

B7-33 is a single-chain synthetic peptide analogue engineered to function as a selective agonist at the relaxin family peptide receptor 1 (RXFP1). Unlike full-length relaxin-2, B7-33 isolates and activates a specific downstream signalling pathway, making it a precise and valuable molecular tool for cardiovascular and fibrotic disease research. Researchers investigating cardioprotection, tissue remodelling, and anti-fibrotic mechanisms have identified B7-33 as a compelling subject of study due to its receptor selectivity and structural simplicity. Direct Anti Peptide supplies this compound in a convenient nasal spray format, optimised for controlled laboratory delivery and experimental consistency.

Peptide Structure & Amino Acid Sequence

B7-33 is a truncated, single-chain peptide derived from the B-chain of human relaxin-2. Its design eliminates the A-chain while retaining the critical binding domain responsible for RXFP1 receptor engagement. This structural simplification preserves the core pharmacophore required for receptor activation while offering improved synthetic accessibility and stability. The peptide’s linear architecture distinguishes it from the heterodimeric structure of native relaxin, making it a tractable research tool for receptor binding studies and downstream signalling investigations.

Chemical & Physical Characteristics

• Type: Synthetic single-chain peptide
• Target Receptor: Relaxin Family Peptide Receptor 1 (RXFP1)
• Format: Nasal spray solution
• Purity: ≥98% (HPLC verified)
• Appearance: Clear to slightly opalescent aqueous solution
• Solubility: Water-soluble; formulated in an aqueous nasal spray vehicle
• Storage Conditions: Refrigerated at 2–8°C; protect from light and repeated freeze-thaw cycles

The nasal spray format provides a stable, ready-to-use liquid presentation that supports consistent volumetric dosing in laboratory settings without the need for reconstitution procedures.

Purity & Analytical Verification (HPLC & MS)

Every batch of B7-33 Nasal Spray supplied by Direct Anti Peptide undergoes rigorous analytical verification prior to release. High-performance liquid chromatography (HPLC) confirms compound purity at ≥98%, while mass spectrometry (MS) validates the molecular identity and structural integrity of the peptide. These dual-method quality controls ensure that researchers receive a compound that meets the exacting standards required for reproducible experimental outcomes. Certificate of Analysis (CoA) documentation is available upon request and accompanies each order.

Quality Control & Lyophilization Integrity

While B7-33 Nasal Spray is supplied in liquid formulation rather than lyophilised powder, the same stringent quality control protocols apply. The aqueous formulation is prepared under controlled conditions to maintain peptide stability, prevent aggregation, and ensure homogenous distribution throughout the solution. Batch-to-batch consistency is maintained through standardised manufacturing processes, and each unit is inspected for particulate matter, clarity, and fill volume prior to dispatch from Direct Anti Peptide.

Safety, Handling & Laboratory Precautions

B7-33 Nasal Spray is a research-grade compound intended exclusively for use by qualified laboratory professionals in appropriate research settings. Standard laboratory safety protocols must be observed at all times. Researchers should wear appropriate personal protective equipment (PPE), including gloves, eye protection, and lab coats, when handling this compound. This product is not approved for administration to humans or animals, and any such use is strictly prohibited. Disposal must comply with applicable institutional and local regulations governing peptide research materials.

Reconstitution, Packaging & Storage

B7-33 Nasal Spray is supplied in a ready-to-use liquid format and does not require reconstitution. The product is packaged in sterile, sealed nasal spray bottles to preserve formulation integrity during transit and storage. Upon receipt, store the product refrigerated at 2–8°C, away from direct light and heat sources. Avoid repeated opening and exposure to ambient conditions to maintain compound stability throughout the research period. Do not freeze the liquid formulation unless specifically indicated by your institutional protocols.

Intended Research Use & Market Positioning

B7-33 Nasal Spray is positioned as a premium research tool for scientists and institutions investigating RXFP1 receptor biology, cardiovascular fibrosis, anti-inflammatory signalling pathways, and tissue remodelling mechanisms. Its selective receptor agonism makes it particularly relevant for studies examining cardiac function, extracellular matrix regulation, oxidative stress responses, and pulmonary or organ fibrotic conditions. Direct Anti Peptide offers this compound as part of a broader catalogue of high-purity research peptides, serving academic, pharmaceutical, and independent research communities worldwide.

Ordering, Availability & Fulfillment

B7-33 Nasal Spray is available to buy online now through Direct Anti Peptide. We offer competitive best-price positioning across our research peptide catalogue, with fast order processing and reliable international fulfillment. All orders are dispatched with full documentation, including batch-specific CoA data. Whether you are looking to order now for an ongoing study or sourcing B7-33 for sale as part of a new research programme, Direct Anti Peptide provides a streamlined purchasing experience backed by verified quality assurance.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. B7-33 Nasal Spray is sold exclusively as a laboratory research compound. It has not been evaluated or approved by any regulatory authority for therapeutic, prophylactic, or diagnostic use in humans or animals. Purchasers are solely responsible for ensuring compliance with all applicable local, national, and international laws and regulations governing the procurement and use of research peptides. Direct Anti Peptide assumes no liability for any misuse, improper handling, or non-compliant application of this product.